Ipsen in Ireland

Ipsen has been in Ireland for over 30 years and its Dublin manufacturing facility produces the active ingredients for two of the company’s oncology treatments.

Improving the lives of patients is what drives us

Ipsen’s team in Ireland spans across several functions, including research & development, manufacturing, and commercial functions, with the team committed to delivering transformative medicines that improve the lives of patients in need across three therapeutic areas – oncology, rare diseases and neuroscience. Additionally, Ipsen has a long-standing commitment to promoting careers in science and STEM, and has a variety of graduate and apprenticeship schemes open to young people with a passion for science.

Our site in Ireland

Dublin, Dublin County, Ireland

Ipsen has been present in Ireland since 1989, pioneering innovation across manufacturing, research and development (R&D) and commercial activities at its site in Blanchardstown, Dublin. Ipsen Ireland employs approximately 190 staff in Ireland including a team of over 20 chemists and analysts in the R&D team who focus on the development of active pharmaceutical ingredients. Since 2005, the R&D team in Dublin has expanded from two people to over 20 today. The group is part of the broader pharmaceutical development group and aiming to realise the company’s ambition of launching one NME (new molecular entity) or meaningful indication per year.

Our partnerships and contributions

At Ipsen, we strive to be a creative and like-minded partner of choice. We believe that achieving the best results for patients depends on our ability to work effectively and ethically in partnership with those around us, including healthcare professionals, the Health Service Executive (HSE) , patient groups, policy makers and government. 

In Ireland, our expert team is united in its mission to build on this legacy and continue delivering unparalleled specialty care active pharmaceutical ingredients (APIs) that create a brighter future for patients living with niche and life-threatening diseases.

Our partnership and contributions


November 2023

© Ipsen Group 2024